← All trials
NCT03665207
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2018
- Primary completion
- Sep 30, 2021
- Completion date
- Sep 30, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 9230
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- Katholieke Universiteit LeuvenReponsible party - principal investigator
- Katholieke Universiteit LeuvenStudy director
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Katholieke Universiteit LeuvenCollaborator
- Government of BelgiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.